QDEL QuidelOrtho Corp

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: global diagnostics provider specializing in immunoassay, molecular testing, clinical chemistry, transfusion medicine, and POC solutions
• • Initiated wind-down of U.S. donor screening portfolio (VIP platform, microplate assays) starting Feb 2024, expected substantially complete by mid-2026

Risk Factors

• • Legal/regulatory risk: FDA EUA approvals and compliance with anti-bribery and data privacy laws impacting product commercialization and operations
• • Geopolitical/macro risk: April 2025 U.S. tariffs on imports from U.K., Canada, Mexico, China causing incremental supply chain and shipping costs

Management Discussion & Analysis

• • Revenue $2,730.2M FY25, down 2% YoY from $2,782.9M; FY24 down 7% YoY from $2,997.8M, COVID-19 product declines primary driver
• • Operating margin approx. 20.1% FY25 (Operating expenses $1,488.9M = 54.5% of revenue), cost of sales 53.3% vs 53.8% in FY24; margin benefit from cost savings initiatives

What are the latest QDEL SEC filings in 2026?

QuidelOrtho Corp (QDEL) has filed a 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 6, 2025, an 8-K current report on April 15, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did QDEL file its most recent 10-K annual report?

QuidelOrtho Corp (QDEL) filed its most recent 10-K annual report on February 19, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view QDEL 10-Q quarterly reports?

QuidelOrtho Corp (QDEL)'s most recent 10-Q quarterly report was filed on November 6, 2025. SignalX displays every QDEL 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has QDEL filed recently?

QuidelOrtho Corp (QDEL)'s most recent 8-K was filed on April 15, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find QDEL insider trading activity (Form 4)?

SignalX aggregates every QDEL Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does QDEL file with the SEC?

QuidelOrtho Corp (QDEL) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new QDEL filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for QuidelOrtho Corp (QDEL).

What is QDEL's SEC CIK number?

QuidelOrtho Corp (QDEL)'s SEC CIK (Central Index Key) number is 1906324. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1906324 to look up all QDEL filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find QDEL return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from QuidelOrtho Corp (QDEL) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.